Back to School 2020
Hamburg on how COVID-19 collaboration models could propel drug development for public health priorities: a BioCentury audio interview
Poor preparedness for this pandemic calls for a commitment to ensure a better response in the future, says Hamburg
Poor preparedness for this pandemic calls for a commitment to ensure a better response in the future, says former FDA Commissioner Margaret Hamburg.
The extraordinary collaboration and commitment on the part of biopharma companies and governments that COVID-19 has inspired should serve as models for addressing unmet medical needs after the crisis has passed, Margaret Hamburg, who served as FDA Commissioner in 2009-15, told BioCentury.
“We've seen the ecosystem of medical product development behaving very differently in the context of COVID, and I think there are important lessons to be learned and applied going forward,” said Hamburg in a BioCentury Back to School audio interview. The conversation was one of a series of BioCentury’s Back to School 2020 audio interviews with industry leaders (see Cover Story: “The Imperative of COVID-19”).
One of those lessons, Hamburg said, is the need to break the “alarm and hit the snooze button phenomenon” that